PharmaShots | Incisive News in 3 Shots

Subscribe Now

MorphoSys

$MorphoSys and Incyte Presents Five-Year P-II Study (L-MIND) Results of Monjuvi (tafasitamab-cxix) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma AACR 2023$

MorphoSys and Incyte Presents Five-Year P-II Study (L-MIND) Results of Monjuvi (tafasitamab-cxix) for Relapsed or Refractory Diffu...

April 17, 2023

MorphoSys Reports the Completion of Patient Enrollment in P-III Study (MANIFEST-2) of Pelabresib for Myelofibrosis

MorphoSys Reports the Completion of Patient Enrollment in P-III Study (MANIFEST-2) of Pelabresib for Myelofibrosis

April 5, 2023

$MorphoSys Reports (L-MIND) Study Results of Monjuvi (tafasitamab-cxix) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma$

MorphoSys Reports (L-MIND) Study Results of Monjuvi (tafasitamab-cxix) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

September 29, 2022

MorphoSys Entered into a License Agreements with HIBio to Develop and Commercialize Felzartamab and MOR21 for Autoimmune and Inflammatory Diseases

MorphoSys Entered into a License Agreements with HIBio to Develop and Commercialize Felzartamab and MOR21 for Autoimmune and Infla...

June 15, 2022

PharmaShots Weekly Snapshots (August 23, 27, 2021)

PharmaShots Weekly Snapshots (August 23, 27, 2021)

August 27, 2021

PharmaShots' Key Highlights of Second Quarter 2021

PharmaShots' Key Highlights of Second Quarter 2021

July 7, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us